Gibson, Dunn & Crutcher advised KKR on the acquisition of Vivitide Inc. by the global investor’s new life sciences portfolio company Biosynth Carbosynth.
Vivitide is a Gardner, Massachusetts-based maker of custom peptides and antibodies for the biotech industry.
McDermott Will & Emery said it represented Ampersand Capital Partners, Vivitide’s previous owner, which will roll over its entire stake and retain a “substantial” minority stake in the combined company.
Together, KKR and Ampersand plan to accelerate the combined company’s geographic expansion, broaden its capabilities, and expand its product portfolio, according to a statement.
“This acquisition marks an important milestone in our ambitious journey to become a leading global partner providing critical materials to the biopharma and diagnostics industries,” said Dr. Urs Spitz, CEO and president of Biosynth Carbosynth, in a statement.
Gibson Dunn said it also advised KKR on the closing of its investment in Biosynth Carbosynth, which was announced November 2021.
To contact the correspondent on this story: Rick Mitchell in Paris at rmitchell@correspondent.bloomberglaw.com
To contact the editor on this story: Chris Opfer in New York at copfer@bloomberglaw.com John Hughes in Washington at jhughes@bloombergindustry.com
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.